The monotherapy of anti-PD-1 antibody showed minimal antitumor activity, while the combination therapy of RocA and anti-PD-1 antibody significantly suppressed tumor growth in both melanoma and colorectal cancer mouse models (Fig. 2D-I). Here, PDCD1 is linked to melanoma.